Market Overview

ZELTIQ Aesthetics Secures Settlement, Permanent Injunction Against Marco Hallerbach

Related ZLTQ
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
The FED Continues To Taper; Indices Rebound Slightly

ZELTIQ Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced it successfully secured an unopposed settlement and permanent injunction against Marco Hallerbach, MD, doing business as Dr. Hallerbach & Associates. ZELTIQ first filed suit in October 2012 with the United States District Court for the Middle District of Florida, Tampa Division, against Dr. Hallerbach for false advertising, false designation of origin, unfair competition, trademark infringement, and unfair and deceptive trade practices.

ZELTIQ is the exclusive licensee of Cryolipolysis, the patented technology behind the aesthetic procedure marketed as CoolSculpting®. Cryolipolysis is the non-invasive cooling of adipose tissue to induce lipolysis – the breaking down of fat cells – to reduce body fat without damage to other tissues.

Posted-In: News Legal

 

Related Articles (ZLTQ)

Around the Web, We're Loving...

Get Benzinga's Newsletters